Unique Ingredient Identifier EWQ57Q8I5X is listed as a ingredient substance
| RN | 64044-51-5 |
| NCIT | C76719 |
| RXCUI | 1305527 |
| PUBCHEM | 104938 |
| MF | C12H22O11.H2O |
| INCHI KEY | WSVLPVUVIUVCRA-KPKNDVKVSA-N |
| SMILES | O.OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O |
UNII EWQ57Q8I5X LACTOSE MONOHYDRATE is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| BUCCAL | TABLET | 21.38 MG |
| IM - IV | INJECTABLE | 2.5 % |
| IM - IV | INJECTION | 2.5 % |
| IM - IV | POWDER | 2.75 % |
| IM - IV | POWDER, FOR INJECTION SOLUTION | 2.5 % |
| IM - IV - SC | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 10.7 % |
| IM - SC | INJECTION | 2.1 % |
| INHALATION | POWDER | 24.95 MG |
| INHALATION | POWDER | 2.5 % |
| INHALATION | POWDER, FOR INHALATION | 2.2 MG/INH |
| INTRACAVITARY | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 4.54 % |
| INTRAMUSCULAR | INJECTION | 5 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | 10.7 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 5 % |
| INTRAVENOUS | INJECTION | 4.5 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 10.7 % |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 69 % |
| IV - SC | INJECTION | 4.9 % |
| IV(INFUSION) | INJECTABLE | 4.5 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 20 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 1 %W/V |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 394.9 MG/Vial |
| IV(INFUSION) | POWDER, FOR INJECTION SUSPENSION, LYOPHILIZED | 9.5 %W/V |
| ORAL | CAPSULE | 430.42 MG |
| ORAL | CAPSULE (IMMED./COMP. RELEASE) | 112 MG |
| ORAL | CAPSULE (IMMED./COMP. RELEASE), HARD GELATIN | 166.77 MG |
| ORAL | CAPSULE, COATED | 99.5 MG |
| ORAL | CAPSULE, COATED PELLETS | 33.09 MG |
| ORAL | CAPSULE, COATED, HARD GELATIN | 85 MG |
| ORAL | CAPSULE, COATED, SOFT GELATIN | 178.91 MG |
| ORAL | CAPSULE, DELAYED ACTION | 125.09 MG |
| ORAL | CAPSULE, DELAYED ACTION, COATED | 16 mg |
| ORAL | CAPSULE, DELAYED RELEASE | 76.4 MG |
| ORAL | CAPSULE, ENTERIC COATED PELLETS | 100 MG |
| ORAL | CAPSULE, EXTENDED RELEASE | 536.4 MG |
| ORAL | CAPSULE, HARD GELATIN | 199.5 MG |
| ORAL | CAPSULE, SUSTAINED ACTION | 147.6 MG |
| ORAL | CAPSULE, SUSTAINED ACTION, HARD GELATIN | 18.8 MG |
| ORAL | DISPERSIBLE TABLET | 543.6 MG |
| ORAL | GRANULE | 109.8 MG |
| ORAL | GRANULE, FOR ORAL SOLUTION | 1691.8 MG/SACHET |
| ORAL | GRANULE, FOR SUSPENSION | NA |
| ORAL | POWDER, FOR SUSPENSION | NA |
| ORAL | TABLET | 708.9 MG |
| ORAL | TABLET | 333 MEQ |
| ORAL | TABLET (IMMED./COMP. RELEASE), COATED | 254 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), FILM COATED | 269.8 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 100 MG |
| ORAL | TABLET, CHEWABLE | 126.1 MG |
| ORAL | TABLET, COATED | 346.5 MG |
| ORAL | TABLET, CONTROLLED RELEASE | 152.75 MG |
| ORAL | TABLET, DELAYED ACTION | 385.55 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 157.95 MG |
| ORAL | TABLET, DELAYED RELEASE | 245 mg |
| ORAL | TABLET, ENTERIC COATED PARTICLES | 150 MG |
| ORAL | TABLET, EXTENDED RELEASE | 538 MG |
| ORAL | TABLET, FILM COATED | 587.44 MG |
| ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 72.14 MG |
| ORAL | TABLET, FOR SUSPENSION | 4.9 MG |
| ORAL | TABLET, MULTILAYER, COATED | 22.7 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 29.75 MG |
| ORAL | TABLET, REPEAT ACTION | 155.28 MG |
| ORAL | TABLET, SUSTAINED ACTION | 299.2 MG |
| ORAL | TABLET, SUSTAINED ACTION, FILM COATED | 260 MG |
| ORAL | TABLET, SUSTAINED RELEASE, FILM COATED | 81.9 MG |
| ORAL-20 | TABLET | 288.75 mg |
| RESPIRATORY (INHALATION) | POWDER, FOR INHALATION | 2 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION | 10.7 % |
| SUBLINGUAL | TABLET | 191.76 MG |
| SUBLINGUAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL | 160.4 MG |
| VAGINAL | EMULSION, CREAM | NA |
| VAGINAL | INSERT | 210 MG |
| VAGINAL | TABLET | 596 MG |
| VAGINAL | TABLET, FILM COATED | 17.9 MG |